Sayjal Patel is an Ophthalmology physician affiliated with Kaiser Permanente. OpenAlex indexes 10 publications with 212 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bard Peripheral Vascular, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
75.9%Prostaglandin Analog21.2%Latanoprost100%Part D≥37 patientsCarbonic Anhydrase Inhibitor19.5%Dorzolamide-Timolol100%Part D≥35 patients+ 2 more classes in this area
Anti-infectives
11.3%Fluoroquinolone Antibacterial8.2%Moxifloxacin100%Part D≥40 patientsMacrolide3.2%Erythromycin100%Part D<11 patientsMusculoskeletal
10.2%Cyclooxygenase Inhibitor7.4%Ketorolac Tromethamine100%Part D≥11 patientsNonsteroidal Anti-inflammatory Drug2.8%Diclofenac Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Progression of Macular Ischemia Following Intravitreal Bevacizumab
Ophthalmic surgery, lasers & imaging retina
2009 - AtypicalBartonella hensalaeChorioretinitis in an Immunocompromised Patient
Ocular Immunology and Inflammation
2008
Similar KOLs
Other experts from the same institution or the same specialty.
Louis Fehrenbacher, MD
Kaiser Permanente
Susy Peng, MD
Kaiser Permanente
Prasanth Manthena, MD
Kaiser Permanente
Alan Go, MD
Kaiser Permanente
Robert Weinreb, MD
University of California San Diego
Emily Chew, MD
National Eye Institute
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”